MeSH D010188 - exocrine pancreatic insufficiency
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D010182:Pancreatic diseases
0 Companies
0 Drugs
Success rate
D010188:
Exocrine pancreatic insufficiency
D000081003:Shwachman-diamond syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AbbVie | Pancrelipase | Creon | 2009-04-30 | $1,248 M | Q2/23-Q1/24 | |
| Digestive Care | Pancrelipase | Pertzye | 2012-05-17 | |||
| Organon | Pancrelipase | Cotazym | 1996-12-09 | |||
| Viokace | Pancrelipase | Viokace | 2012-03-01 | |||
| Vivus | Pancrelipase | Pancreaze | 2010-04-12 | $22.008 M | Q2/19-Q1/20 | |
| Zenpep | Pancrelipase | Zenpep | 2009-08-27 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
67%2/3
Phase 3
67%2/3
Approved: 1Overall Success rate: 44%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use